Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir
Open Access
- 23 November 2012
- journal article
- research article
- Published by Elsevier BV in Journal of Hepatology
- Vol. 58 (4), 646-654
- https://doi.org/10.1016/j.jhep.2012.11.012
Abstract
No abstract availableFunding Information
- Bristol-Myers Squibb
This publication has 21 references indexed in Scilit:
- Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)Antimicrobial Agents and Chemotherapy, 2012
- Resistance Analysis of the Hepatitis C Virus NS3 Protease Inhibitor AsunaprevirAntimicrobial Agents and Chemotherapy, 2012
- Hepatitis C Viral Evolution in Genotype 1 Treatment-Naïve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical TrialsPLOS ONE, 2012
- Single- and Multiple-Ascending-Dose Studies of the NS3 Protease Inhibitor Asunaprevir in Subjects with or without Chronic Hepatitis CAntimicrobial Agents and Chemotherapy, 2012
- Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevirJournal of Clinical Virology, 2011
- Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo CorrelationsHepatology, 2011
- An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver DiseasesHepatology, 2011
- Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon SystemAntimicrobial Agents and Chemotherapy, 2010
- A perspective on modelling hepatitis C virus infectionJournal of Viral Hepatitis, 2010
- In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435Antimicrobial Agents and Chemotherapy, 2010